check_circleStudy Completed

Constipation

Bayer Identifier:
18129
ClinicalTrials.gov Identifier:
NCT01212445
EudraCT Number:
2010-021367-32
EU CT Number:
Not Available
Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)

Trial purpose

The primary objective of the study was to evaluate the proportion of subjects with a bowel movement (BM) without straining or without hard and/or lumpy stool within the first 24 h of treatment for subjects taking 1 of 3 single doses of Polyethylene Glycol (PEG) plus Electrolytes (PEG+E) (13.125 g, 26.25 g, 39.375 g). The doses specified relate to the doses of PEG. Secondary objectives were measured by analysis of a subject diary and self-reported BM data. The secondary objectives included comparisons of PEG+E doses at 24 h for: BM control; relief of gas; relief of bloating; and relief of abdominal discomfort/cramping.
In addition, the proportion of subjects with a BM (without straining and without hard and/or lumpy stool) within the first 24 h of treatment for subjects taking different doses of PEG+E was evaluated for the time to first BM.

Key Participants Requirements

Sex

Both

Age

18 - N/A
  • - A willingness to participate in the study and comply with its procedures
    - Must be ambulatory
    - Male or female subjects aged 18 years or older who met two or more of the following modified Rome III-based criteria for constipation: (a) straining during at least 25% of defecations; (b) lumpy or hard stools in at least 25% of defecations; (c) sensation of incomplete evacuation for at least 25% of defecation; (d) sensation of anorectal obstruction/blockage for at least 25% of defecations; (e) manual maneuvers to facilitate at least 25% of defecations (eg, digital evacuation, support of the pelvic floor), and (f) fewer than 3 defecations per week
    - Criteria fulfilled for the last 3 months with symptom onset at least 6 mo prior to diagnosis
    - Had a self reported or documented history of chronic constipation
    - Agreed not to use laxatives other than the study treatment from baseline/informed consent to end-of-study
    - Agreed to maintain a similar diet from the week before Visit 3 to the end-of-study were to be enrolled
    - Additionally required not to use any treatment known to cause constipation during the study (for subjects enrolled after Amendment 1)
    - If a female subject, either surgically sterile, 2 years postmenopausal, or using an acceptable method of contraception. Abstinence was not an acceptable method of contraception. Females of childbearing potential had to have a urine pregnancy test (human chorionic gonadotropin [HCG]) that was negative at Visit 3
    - Be able to read and write in the diaries in English
  • - Had loose stools without the use of laxatives
    - Recurrent abdominal pain
    - Known or suspected bowel perforation, obstruction, or fecal impaction; or
    had gastric retention, inflammatory bowel disease, bowel resection, or
    colostomy
    - Celiac disease or known gluten sensitivity
    - Known renal or hepatic insufficiency
    - Recent history of alcohol abuse or drug abuse
    - History of psychiatric disorders
    - History of significant ongoing medical problems or scheduled for surgical procedures
    - Subjects who, in the opinion of the Investigator, should not have been
    included in the study for any reason, including inability to follow study
    procedures
    - Participated in an investigational clinical, surgical, drug or device study within the past 30 days
    - Pregnant or lactating
    - Allergic to PEG or PEG+E
    - Employed by or have immediate family members employed by a company that manufactures laxative products
    - Participant or family member of the Investigator or site staff directly involved with this study

Trial summary

Enrollment Goal
154
Trial Dates
October 2010 - November 2011
Phase
Phase 2
Could I Receive a placebo
No
Products
Transipeg (Macrogol, BAY81-8430)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Suite 2.6 Consultants Private Clinicork, Ireland

Primary Outcome

  • Proportion of subjects with successful BM within 24 h of dosing
    A successful BM was defined as a BM with no straining or hard/lumpy stools
    date_rangeTime Frame:
    Throughout the course of the 24 h treatment period
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Proportion of subjects with successful BM within 12 h of dosing
    A successful BM was defined as a BM with no straining or hard/lumpy stools
    date_rangeTime Frame:
    Throughout the course of the 12 h treatment period
    enhanced_encryption
    Safety Issue:
    No
  • Time to first successful BM
    date_rangeTime Frame:
    Throughout the course of the 24 h treatment period
    enhanced_encryption
    Safety Issue:
    No
  • Visual Analogue Scale (VAS) ratings for BM control
    The BM control VAS uses a 100 mm horizontal line with the two ends representing the opposite, extreme limits of the participant's experience of BM control. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. BM Control ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=Calm, not urgent and 100 mm= Not able to hold BM, very urgent
    date_rangeTime Frame:
    Throughout the course of the 24 h treatment period
    enhanced_encryption
    Safety Issue:
    No
  • VAS ratings for gas
    The Gas VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related gas. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Gas ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe
    date_rangeTime Frame:
    Throughout the course of the 24 h treatment period
    enhanced_encryption
    Safety Issue:
    No
  • VAS ratings for bloating
    The Bloating VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related bloating. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Bloating ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Severe
    date_rangeTime Frame:
    Throughout the course of the 24 h treatment period
    enhanced_encryption
    Safety Issue:
    No
  • VAS ratings for abdominal discomfort/cramping
    The Abdominal Discomfort/Cramping VAS uses a 100 mm horizontal line with the two ends representing opposite, extreme limits of the participant's experience with BM-related abdominal discomfort/cramping. Participants marked where they felt they resided between the two ends with a vertical line. The distance from the left end of the VAS (0 mm) to the participant's mark was measured and recorded in mm. Abdominal discomfort/cramping ratings ranged on a continuous scale from 0 to 100 mm, where 0 mm=None and 100 mm= Painful
    date_rangeTime Frame:
    Throughout the course of the 24 h treatment period
    enhanced_encryption
    Safety Issue:
    No
  • Subject’s Global Assessment of treatment
    At the End of Study Visit, the study staff asked the participant to rate their global assessment of the study treatment according to the following categories: 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, 4 = extremely effective
    date_rangeTime Frame:
    Throughout the course of the 24 h treatment period
    enhanced_encryption
    Safety Issue:
    No
  • Number of participants with adverse events
    date_rangeTime Frame:
    Between 6 and 16 days
    enhanced_encryption
    Safety Issue:
    Yes

Trial design

A Randomized, Open-Label, Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
Open Label
Assignment
Parallel Assignment
Trial Arms
3

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find information about studies related to Bayer Healthcare products conducted in Europe.Click here to find results for studies related to Bayer Healthcare products.